Suzhou Genhouse Bio Co., Ltd.
11
5
7
0
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 11 trials
0%
0 trials in Phase 3/4
0%
0 of 0 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
A Study to Evaluate Safety, PK and Efficacy of GH55 in Combination With GH21 in Patients With Solid Tumors
Role: lead
Phase 2 Clinical Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of GH21 Capsules Combined With D-1553 Tablets in Subjects With Locally Advanced or Metastatic Solid Tumors With the KRASG12C Mutation
Role: lead
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of GH2616 in Subjects With Advanced Solid Tumor.
Role: lead
A Phase Ia/Ib Clinical Study of GH56 Capsules in Subjects With MTAP-Deleted Advanced Solid Tumors
Role: lead
A Study of GH21 Combined With Previous Target Therapy or Immunotherapy in Patients With Advanced Solid Tumors
Role: lead
GH21 Capsules for Advanced Solid Tumors: A Study on Safety and Early Results
Role: lead
GH21 Combined With D-1553 in KRAS G12C Mutant Advanced Solid Tumors
Role: lead
GH35 Tablets for Advanced Solid Tumors: A Study on Safety and Early Results
Role: lead
A Phase Ia/Ib Study of GH2616 Tablet in Subjects With Advanced Solid Tumors
Role: lead
GH55 for Advanced Cancers With MAPK Mutations: A Study on Safety and Early Results
Role: lead
A Phase Ib/II Clinical Study of GH21 Capsules Combined With Osimertinib Mesylate Tablets in Patients With NSCLC
Role: lead
All 11 trials loaded